Last reviewed · How we verify
AMG 073
AMG 073 is a calcimimetic agent that allosterically activates the calcium-sensing receptor on the parathyroid gland, increasing its sensitivity to extracellular calcium and thereby suppressing parathyroid hormone secretion.
AMG 073 is a calcimimetic agent that allosterically activates the calcium-sensing receptor on the parathyroid gland, increasing its sensitivity to extracellular calcium and thereby suppressing parathyroid hormone secretion. Used for Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
At a glance
| Generic name | AMG 073 |
|---|---|
| Sponsor | Amgen |
| Drug class | Calcimimetic agent |
| Target | Calcium-sensing receptor (CaSR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Nephrology |
| Phase | FDA-approved |
Mechanism of action
By binding to an allosteric site on the calcium-sensing receptor, AMG 073 enhances the receptor's ability to detect circulating calcium levels, leading to decreased PTH production and secretion. This results in lower serum calcium and phosphorus levels in patients with secondary hyperparathyroidism. The drug is particularly useful in dialysis patients where conventional treatments are inadequate.
Approved indications
- Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis
Common side effects
- Hypocalcemia
- Nausea
- Vomiting
- Diarrhea
- Headache
Key clinical trials
- The Trial of SHR6508 in Secondary Hyperparathyroidism (PHASE3)
- Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism (PHASE3)
- Novel Combination Therapy for Osteoporosis in Men (PHASE4)
- Effect of Whole-body Vibration Training in Patients With Renal Dialysis (NA)
- Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet
- DePTH: De-emphasize PTH (PHASE2)
- Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients (PHASE1, PHASE2)
- A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 073 CI brief — competitive landscape report
- AMG 073 updates RSS · CI watch RSS
- Amgen portfolio CI